Evidence map›Paper›PMID 33391614›Full record

ArticleWorld journal of cardiology2020

Safety and performance of the EverPro

Rahul Trimukhe, Preeti Vani, Arvind Patel, Vikas Salgotra

Open access · diamondAbstract read
In one paragraph

Article in World journal of cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Rahul TrimukheDepartment of Cardiology, Atma Malik Hospital, Ahmednagar 423601, Maharashtra, India.
Preeti VaniSLTL Medical Division, SLTL (Sahajanand Laser Technology Ltd.), Gandhinagar 382016, Gujarat, India.
Arvind PatelSLTL Group, SLTL (Sahajanand Laser Technology Ltd.), Gandhinagar 382016, Gujarat, India.
Vikas SalgotraSLTL Medical Division, SLTL (Sahajanand Laser Technology Ltd.), Gandhinagar 382016, Gujarat, India. clinical@sltl.com.
SMT (India) · INAhmedabad Civil Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe EverPro

aimTo determine the safety and performance of the EverPro

methodsThis observational, retrospective, single-center study enrolled patients who had been implanted with the EverPro

resultsThe study population comprised 77 patients (98 lesions). A total of 37 (48.1%) patients had comorbid hypertension. In total, 26 (33.8%) patients presented with ST segment elevation MI and 10.4% patients with non-ST segment elevation MI. Treated lesions were located mainly in the left anterior descending artery (49%) followed by the right coronary artery (29.6%), left circumflex (12.2%) and obtuse marginal (9.2%) arteries. The majority of patients were with single-vessel disease (79%), 22.2% of lesions had a mild to severe thrombus load, and 94.9% were American College of Cardiology/American Heart Association type B or C.

conclusionThese findings suggest that the EverPro

Indexed as

Coronary artery diseaseEverolimusMajor adverse cardiac eventRetrospective, EverProTM, Myocardial infarction

Identifiers

PMID33391614
PMCPMC7754385
OpenAlexW3110975446

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.